Global Hormone Replacement Therapy Market Precise Study on Factors, Drivers and Key Players Strategies Analyzed Till 2028 || Competition Landscape- Eli Lilly and Company, Endo Pharmaceuticals, F. Hoffmann-La Roche Ltd., Merck KGaA, Mylan N.V., Novartis AG

The hormone replacement therapy market is a fragmented landscape with presence of few tier one companies and upcoming players. Top five companies involved in the hormone replacement therapy formulations account for a significant share of the overall hormone replacement therapy market. Top 5 players – Novo Nordisk, Pfizer Inc., Janssen NV (a Johnson & Johnson company), Novartis AG and Bayer AG collectively – collectively account for 35 percent revenue share of the hormone replacement therapy market from on the global front.

Get Free Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=2224

The hormone replacement therapy market is foreseen to expand at a significant pace with sales of hormone replacement therapy products crossing US$ 12,000 Mn by 2019 end. Rising incidences of osteoporosis fractures coupled with growing menopause rates among women have remained instrumental in driving the demand for hormone replacement therapy. Fact.MR envisages that the demand for hormone replacement therapy is projected to expand at a CAGR of 6.0% in terms of value throughout the period of forecast, 2018-2028.

Disorders associated with hormonal imbalance continue to influence the use of hormone replacement therapy worldwide. Hormone replacement therapy demand is further pushed with macroeconomic aspects such as growing geriatric population and significant increase in healthcare expenditure worldwide. Growing age directly impacts secretion of hormones such as progesterone and estrogen in women, which is expected to trigger the use of estrogen hormone replacement therapy.

Use of Low Cost Generic Versions of Hormone Replacement Therapy Drugs – An Upcoming Trend

Affordability has always remained a major challenge for any pharmaceutical drug or formulation. Moreover, insufficient healthcare reimbursements have resulted in individuals opting for cheaper drugs with unclear drug effectiveness. This prompted manufactures of hormone replacement therapy drugs to produce generic versions of the formulations in a bid to bridge the gap between purchasing power of people and hormone replacement therapy drug pricing. Companies developing generic hormone replacement therapy drugs are also acquiring FDA approvals, which is direct inference apropos to drug effectiveness. For instance, Teva pharmaceuticals has introduced generic version of Estrace cream and estradiol vaginal cream in 2018. The trend is expected to auger well for the overall growth of the hormone replacement therapy market.

Rising Prevalence of Osteoporosis to Influence Hormone Replacement Therapy Demand

Growing life expectancy is closely associated with degeneration that further translates into osteoporotic fractures. In addition, this condition further results in an increase in gap between spine bones during menopause with diminishing estrogen levels. According to the International Osteoporosis Foundation, osteoporosis causes over 8.9 million fractures annually on the global front and is likely to grow in the coming years. Rising prevalence of osteoporosis among women is expected to trigger the demand for hormone replacement therapy.

To Get Complete Report with Table of Content, Visit @ https://www.factmr.com/report/2224/hormone-replacement-therapy-market

Hormone Replacement Therapy Associated with Reduced Dementia – Key Growth Propellant  

Hormone replacement therapy can protect memory which is required to carry out short-term cognitive tasks after menopausal stress. Estrogen-only hormone replacement therapy can facilitate lower stress levels without impacting memory. In addition, hormone replacement therapy also reduces possibilities of both vascular dementia and Alzheimer’s disease.  

Combination Hormone Replacement Therapy Associated with Cancer – Key Growth Deterrent

Use of hormone replacement therapy can lead to cancerous cell development. The use of combination hormone replacement therapy (combination of progesterone and estrogen) can increase the risk of breast cancer by 75 percent even if used for a short timeframe. According to the U.S Women’s Health Initiative, the use of combination hormone replacement therapy comes with the risk of development of several cancers including ovarian and uterus cancers. This aspect is expected to confine the growth in adoption of hormone replacement therapy in the forthcoming years. Other hormone replacement therapy related disorders such as stroke, cardiac disorders and blood clots are further expected to negatively impact the growth of the hormone replacement therapy market.

Competitive Landscape

The report on hormone replacement therapy market offers intelligence on key participants in the hormone replacement therapy market. The key companies involved in the formulation of hormone replacement therapy products are thoroughly assessed and profiled in the report. Various facets of competition including SWOT analysis, product portfolio analysis, drug developments and innovations, strategies and key financials are covered. Key companies profiled in the report include Novartis AG, Novo Nordisk A/S, Teva Pharmaceuticals, Mylan N.V and Pfizer Inc.

Major companies in the hormone replacement therapy market are concentrating on expanding their current product portfolio. New hormone replacement therapy formulations being the core focus, companies are carrying out trials and gain FDA approvals. For instance, Novartis AG’s research and development department delivered 6 critical FDA breakthrough therapy designations and 16 submissions in 2017. In May 2017, Novartis AG announced U.S. FDA’s approval for its hormone replacement therapy tablets for hormone receptor positive and metastatic breast cancer treatment in postmenopausal women.

Market Structure

The hormone replacement therapy market is segmented in detail to cover every angle of the hormone replacement therapy space. The hormone replacement therapy market has been segmented on the basis of product type, by dosage form, by indication, by distribution channel and by region.

Various hormone replacement therapy products such as estrogen hormone replacement therapy, thyroid hormone replacement therapy and growth hormone replacement therapy is covered. By dosage form, hormone replacement therapy market is segmented into tablets, patches, injections, implants and creams. By indications, hormone replacement therapy market is categorized into menopause, osteoporosis, thyroid and growth hormone deficiency. By distribution channel, it is segmented by hospital pharmacies, clinics, retail pharmacies and online pharmacies.

The hormone replacement therapy market is assessed across key regions such as North America, Latin America, Europe, Asia Pacific excluding Japan (APEJ), Middle East and Africa (MEA) and Japan.

Hormone Replacement Therapy Market Report is available for Purchase @ https://www.factmr.com/checkout/2224/S

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Read Industry News at- https://www.industrynewsanalysis.com/

This release was published on openPR.